These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
345 related articles for article (PubMed ID: 35534562)
1. Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. Choudhury A; Magill ST; Eaton CD; Prager BC; Chen WC; Cady MA; Seo K; Lucas CG; Casey-Clyde TJ; Vasudevan HN; Liu SJ; Villanueva-Meyer JE; Lam TC; Pu JK; Li LF; Leung GK; Swaney DL; Zhang MY; Chan JW; Qiu Z; Martin MV; Susko MS; Braunstein SE; Bush NAO; Schulte JD; Butowski N; Sneed PK; Berger MS; Krogan NJ; Perry A; Phillips JJ; Solomon DA; Costello JF; McDermott MW; Rich JN; Raleigh DR Nat Genet; 2022 May; 54(5):649-659. PubMed ID: 35534562 [TBL] [Abstract][Full Text] [Related]
2. Hypermitotic meningiomas harbor DNA methylation subgroups with distinct biological and clinical features. Choudhury A; Chen WC; Lucas CG; Bayley JC; Harmanci AS; Maas SLN; Santagata S; Klisch T; Perry A; Bi WL; Sahm F; Patel AJ; Magill ST; Raleigh DR Neuro Oncol; 2023 Mar; 25(3):520-530. PubMed ID: 36227281 [TBL] [Abstract][Full Text] [Related]
3. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges. Wang B; Cui Z; Zhong Z; Sun Y; Yang GY; Sun Q; Bian L Mol Carcinog; 2016 Dec; 55(12):2268-2277. PubMed ID: 26840621 [TBL] [Abstract][Full Text] [Related]
11. Osteoglycin promotes meningioma development through downregulation of NF2 and activation of mTOR signaling. Mei Y; Du Z; Hu C; Greenwald NF; Abedalthagafi M; Agar NYR; Dunn GP; Bi WL; Santagata S; Dunn IF Cell Commun Signal; 2017 Sep; 15(1):34. PubMed ID: 28923059 [TBL] [Abstract][Full Text] [Related]
12. Meningioma progression in mice triggered by Nf2 and Cdkn2ab inactivation. Peyre M; Stemmer-Rachamimov A; Clermont-Taranchon E; Quentin S; El-Taraya N; Walczak C; Volk A; Niwa-Kawakita M; Karboul N; Giovannini M; Kalamarides M Oncogene; 2013 Sep; 32(36):4264-72. PubMed ID: 23045274 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth. Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902 [TBL] [Abstract][Full Text] [Related]